- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Plant for production of Penicillin G, Clavulanic acid to begin soon: DoP
New Delhi: The production plant for Clavulanic Acid to make Augmentin used for the treatment of various bacterial infections will begin soon, Dr Arunish Chawla, Secretary Department of Pharmaceuticals Ministry of Chemical and Fertilizers informed on Tuesday.
"Production Linked Incentive scheme for bulk drugs and under that scheme, huge investment has come in, and Penicillin G and Clavulanic would now be manufactured in India. Hopefully these plants will be commissioned and inaugurated soon," speaking with ANI she said.
"Half the antibiotics in the market are beta lactam antibiotics. They are basically based on Penicillin G and Clavulanic acid. These are core or key drug intermediates, key starting materials. They are also called bulk drugs. We used to manufacture them at one time, but we lost it to foreign competition." she added.
"We are very happy to announce that the PLI, or the Production linked incentive scheme for bulk drugs has been a success and under that scheme, huge investment has come in, and Penicillin G and Clavulanic would now be made in India," she further stated.
The secretary said that last year India had achieved trade balance in the export and import of bulk drugs.
"In India, bulk drugs should be seen on an aggregate basis. Last year, we achieved trade balance, which means we exported as many bulk drugs as we imported, but certain molecules continue to be imported from one particular country, which means import concentration that potentially could disrupt supply chains when the time comes", Chawla said.
"We need to diversify the value chains for these critical bulk drugs. The PLI scheme has provided incentive so that manufacturing on key starting materials for antibiotics can happen in India, and that's going to commence very soon," she added.
Penicillin G and Clavulanic Acid are key ingredients in the antibiotic Augmentin and the commissioning of the plant will thereby reduce India's dependency on China.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Next Story